GE Aerospace vs Oruka Therapeutics Inc. Common Stock — how do they compare? GE Aerospace trades at $307.31 (market cap $319.19B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: GE Aerospace is far larger — about 61.6× Oruka Therapeutics Inc. Common Stock's market cap, and GE Aerospace pays a 0.61% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Aerospace for 111 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| GE | ORKA | |
|---|---|---|
Market Cap | $319.19B | $5.18B |
Volume | 4,516,693 | 490,798 |
Sector | Industrials | Health |
52-Week High | $381.22 | $113.08 |
52-Week Low | $273.25 | $26.19 |
Typical Hold Time | 111 Days | 0 Days |
Enterprise Value | $329.00B | $4.31B |
Dividend Yield | 0.61% | — |
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $308.64, showing modest daily gains of 0.14% amid mixed technical signals. The stock maintains strong fundamentals with three consecutive quarterly earnings beats, robust 48.79% ROE, and improving profit margins reaching 18.98% in 2025. Recent news highlights the company's $12 billion CPP acquisition to strengthen its aerospace supply chain capabilities while maintaining shareholder returns through dividends and buybacks.
Outlook remains positive with analyst consensus at $409.60 price target (32.7% upside) and no sell ratings. Key opportunities include aerospace demand growth and strategic acquisitions, while risks involve high valuation multiples (P/E 36.28) and integration challenges from recent M&A activity. The bearish technical picture suggests potential near-term consolidation before fundamental strengths drive long-term appreciation.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →